---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-007660"
form_type: "8-K"
ticker: "CODX"
cik: "0001692415"
company_name: "Co-Diagnostics, Inc."
filed_at: "2022-03-24T23:59:59+00:00"
generated_at: "2026-06-26T18:32:33.630155+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Co-Diagnostics reports FY2021 revenue $97.9M, EPS $1.23; guides Q1 FY2022 revenue $21-22M

## Summary
- Revenue $97.9M, +$23.3M YoY; net income $36.7M ($1.23 diluted EPS) vs $42.5M ($1.52) in 2020.
- Adjusted EBITDA $52.1M, up from $45.3M in 2020; cash & securities $89.9M at Dec 31, 2021.
- Q1 FY2022 guidance: revenue $21-22M, diluted EPS $0.17-0.20, shares 32.4M.
- Gross profit $86.3M (88.2% margin); operating income $46.1M on record revenue.
- 2021 highlights: at-home PCR platform, acquisitions of Idaho Molecular & Advanced Conceptions, CDSCO clearance for ABC test in India.

## SEC filing metadata
- accession: 0001493152-22-007660
- form_type: 8-K
- ticker: CODX
- cik: 0001692415
- company_name: Co-Diagnostics, Inc.
- filed_at: 2022-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1692415/000149315222007660/0001493152-22-007660-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1692415/000149315222007660/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-007660
- JSON: https://secwatch.observer/filing/0001493152-22-007660.json
- Plain text: https://secwatch.observer/filing/0001493152-22-007660.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.